This Week in Solar

Recs

0

Be A Motley Fool Millionaire!

David Gardner's top pick took an epic run of 1,334%! See what he’s recommending that you buy NEXT.

Hey there, solar Fools. After a brief earnings season hiatus, we now return to our regularly scheduled solar roundup.

We saw a slew of earnings results this week, from European leading lights Q-Cells and REC Group to wafer whiz LDK Solar (NYSE: LDK) and a freshly cashed up Canadian Solar (Nasdaq: CSIQ). In addition to the dollars and cents, each company had interesting things to say about ongoing technological developments.

REC Group, which handles everything from polysilicon production to module manufacturing, announced that it's working with partner Silicon Genesis to develop an ultra-thin wafer that can "shave years from the industry's goal of reaching grid parity." (Grid parity means having costs per kilowatt-hour on par with electricity derived from fossil fuels.) If REC achieves anything approaching 50-micron thickness in high-volume production, its edge over LDK, Trina Solar (NYSE: TSL), and Yingli Green Energy (NYSE: YGE) would be anything but thin.

Q-Cells, meanwhile, revealed a very strong commitment to upgraded metallurgical grade silicon (UMG). The company expects UMG, a cheaper alternative to virgin polysilicon, to make up about 30% of supply next year, and over half of supply in 2010. That's huge news from one of the top solar cell companies in the world. LDK, meanwhile, is now integrating UMG into a new line of wafers.

The other big news this week was PG&E's (NYSE: PCG) award of two huge solar power plant deals to thin-film start-up OptiSolar and SunPower (NYSE: SPWR). The deals demonstrate that both crystalline and thin-film PV technologies are currently considered economically viable on a large (i.e. several-hundred-megawatt) scale.

Before popping the cork on the champagne, however, I think it's important to consider the caveat that these projects are contingent upon extension of the investment tax credit. This measure continues to meander in Congress, thanks in part to our leading presidential candidates, both of whom failed to vote on the measure before the summer recess. If you're a solar investor or supporter, think about calling your senator and encouraging him/her to get this measure passed.

“Make Big Money With Options” Motley Fool CFO Ollen Douglass recently made over $100,000 buying options on 7 well known stocks. Now we’re committed to turning his small fortune into a massive one! And we want you to join us! Enter your email address to hear more:

Fool contributor Toby Shute doesn't have a position in any company mentioned. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 708393, ~/Articles/ArticleHandler.aspx, 12/1/2009 11:25:47 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
The Public Health-Care Plan's Problem

Related Tickers

12/1/2009 10:44 AM
LDK $8.04 Up +0.24 +3.09%
LDK Solar Co., Ltd… CAPS Rating: ****
PCG $42.80 Up +0.46 +1.09%
PG&E Corp CAPS Rating: *****
TSL $47.21 Up +0.63 +1.35%
Trina Solar Limite… CAPS Rating: **
YGE $14.69 Up +0.48 +3.38%
Yingli Green Energ… CAPS Rating: ****
CSIQ $22.91 Up +0.89 +4.04%
Canadian Solar, In… CAPS Rating: ***

Community: Investing Wiki

Term Of The Hour

PDUFA: The Prescription Drug User Fee Act (PDUFA) is a law enacted by Congress that gives powers to the FDA.

Want to learn more or edit this definition?
Click here to read more!